GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Liabilities-to-Assets

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Liabilities-to-Assets : 0.39 (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Freeline Therapeutics Holdings's Total Liabilities for the quarter that ended in Sep. 2023 was $19.18 Mil. Freeline Therapeutics Holdings's Total Assets for the quarter that ended in Sep. 2023 was $49.22 Mil. Therefore, Freeline Therapeutics Holdings's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 was 0.39.


Freeline Therapeutics Holdings Liabilities-to-Assets Historical Data

The historical data trend for Freeline Therapeutics Holdings's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings Liabilities-to-Assets Chart

Freeline Therapeutics Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Liabilities-to-Assets
0.29 0.13 0.07 0.15 0.40

Freeline Therapeutics Holdings Quarterly Data
Dec18 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.40 0.31 0.33 0.39

Competitive Comparison of Freeline Therapeutics Holdings's Liabilities-to-Assets

For the Biotechnology subindustry, Freeline Therapeutics Holdings's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Freeline Therapeutics Holdings's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Freeline Therapeutics Holdings's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Freeline Therapeutics Holdings's Liabilities-to-Assets falls into.



Freeline Therapeutics Holdings Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Freeline Therapeutics Holdings's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Liabilities-to-Assets (A: Dec. 2022 )=Total Liabilities/Total Assets
=34.227/86.641
=0.40

Freeline Therapeutics Holdings's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 is calculated as

Liabilities-to-Assets (Q: Sep. 2023 )=Total Liabilities/Total Assets
=19.179/49.219
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Freeline Therapeutics Holdings  (NAS:FRLN) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Freeline Therapeutics Holdings Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Headlines